---
TL;DR: PT-141 (bremelanotide) typically comes as a 10mg lyophilized vial. Add 2mL bacteriostatic water for a 5mg/mL stock solution. For a 1mg research dose, draw 0.2mL (20 units on a U-100 insulin syringe). Use the Capital Peptides reconstitution calculator to eliminate manual math errors.

PT-141 (bremelanotide) is a melanocortin receptor agonist β€” specifically MC3R and MC4R β€” studied for its role in sexual function and arousal pathways in both male and female models. Unlike PDE5 inhibitors, PT-141 acts centrally via the hypothalamus rather than peripherally on vascular tissue, making it mechanistically distinct in research contexts. Before any in-vitro or in-vivo work can begin, accurate reconstitution is non-negotiable. A single arithmetic error at the bench compounds across every downstream data point. This guide covers the full PT-141 peptide reconstitution calculator workflow β€” from vial to syringe β€” with the math shown explicitly so researchers can verify every step.

What Is PT-141 and Why Reconstitution Accuracy Matters

PT-141 is a cyclic heptapeptide analog of alpha-melanocyte-stimulating hormone (Ξ±-MSH), derived from the tanning peptide Melanotan II. Its molecular weight is 1025.2 g/mol. Lyophilized (freeze-dried) PT-141 arrives as a white or off-white powder in sealed vials β€” most commonly in 10mg quantities for research supply. The powder is stable at room temperature for short periods but must be reconstituted with a compatible solvent before use.

Why does reconstitution precision matter so much? Because PT-141 research protocols frequently reference dose ranges between 0.5mg and 2mg per study subject. At those small quantities, a 10% dilution error translates directly into a 10% deviation in delivered dose β€” enough to confound results, particularly in dose-response studies.

PT-141 Reconstitution: Concentration Formula Concentration (mg/mL) = Peptide Mass (mg) Γ· Solvent Volume (mL) Example: 10mg Γ· 2mL = 5 mg/mL stock solution Draw Volume (mL) = Desired Dose (mg) Γ· Concentration (mg/mL) Example: 1mg Γ· 5mg/mL = 0.20mL = 20 units on U-100 syringe

Choosing Your Solvent: Bacteriostatic Water vs. Sterile Water

For PT-141 peptide reconstitution, bacteriostatic water (BAC water) is the preferred solvent for research purposes. BAC water contains 0.9% benzyl alcohol as a preservative, inhibiting microbial growth and extending the usability of a reconstituted vial to approximately 28–30 days when stored refrigerated at 2–8Β°C. Sterile water is acceptable for single-use preparations only, as it carries no antimicrobial protection after the vial seal is broken.

Avoid using normal saline (0.9% NaCl) as the primary reconstitution vehicle for PT-141 unless a specific protocol calls for it β€” some peptides aggregate in ionic solutions, and while PT-141 dissolves reasonably well across solvent types, BAC water remains the research standard for preserved vials.

Step-by-Step PT-141 Peptide Reconstitution Protocol

  1. Gather materials: PT-141 vial (10mg lyophilized), bacteriostatic water, 1mL insulin syringe (U-100), alcohol swabs, and a refrigerator-ready storage container.
  2. Disinfect: Wipe the rubber stopper of both the peptide vial and the BAC water vial with fresh alcohol swabs. Allow 30 seconds to dry.
  3. Draw solvent: Using the insulin syringe, draw 2.0mL of bacteriostatic water. If your syringe only holds 1mL, do two separate draws of 1.0mL each.
  4. Inject slowly: Insert the needle into the PT-141 vial at an angle and direct the BAC water stream against the glass wall, not directly onto the lyophilized cake. This prevents foaming and peptide degradation from mechanical shear.
  5. Gentle dissolution: Do NOT shake. Gently swirl or roll the vial between your palms for 30–60 seconds until the powder is fully dissolved. The solution should be clear and colorless.
  6. Label and store: Label with reconstitution date and concentration (5mg/mL). Store at 2–8Β°C, protected from light. Use within 28 days.

If you want to skip the manual calculation entirely, the Capital Peptides peptide reconstitution calculator handles all of this math automatically β€” enter your vial size, desired concentration, and target dose, and it outputs your exact draw volume in both mL and syringe units.

PT-141 Peptide Reconstitution Calculator: The Full Math

Understanding the underlying arithmetic makes you a better researcher β€” and helps you catch errors before they reach the bench. Here are the three most common PT-141 vial sizes and their resulting concentrations with standard solvent volumes:

Vial Size BAC Water Added Stock Concentration Draw for 1mg Dose Syringe Units (U-100)
5mg 1.0mL 5 mg/mL 0.20mL 20 units
10mg 2.0mL 5 mg/mL 0.20mL 20 units
10mg 1.0mL 10 mg/mL 0.10mL 10 units
10mg 4.0mL 2.5 mg/mL 0.40mL 40 units

The 2mL/10mg ratio (5mg/mL) is widely used in research because it keeps draw volumes manageable on a standard U-100 insulin syringe without introducing rounding errors at sub-0.1mL scales. For protocols referencing 0.5mg doses, this gives a clean 10-unit draw β€” easy to read, easy to verify.

U-100 Syringe: PT-141 Dose Reference (5mg/mL stock) 0 10u 0.5mg 20u 1.0mg 30u 1.5mg 40u 2.0mg 50u Stock concentration: 10mg PT-141 in 2.0mL BAC water = 5mg/mL Shaded area = 1.0mg research dose (20 units / 0.2mL)

PT-141 Mechanism of Action in Research Context

PT-141 is a selective melanocortin receptor agonist with high affinity for MC3R and MC4R subtypes. MC4R is densely expressed in the hypothalamus and plays a well-documented role in regulating sexual arousal, feeding behavior, and energy homeostasis. Unlike peripherally acting compounds, PT-141's central mechanism means it works upstream of the vascular response β€” activating dopaminergic pathways in the medial preoptic area (MPOA) that modulate motivation and arousal rather than simply increasing blood flow.

A 2005 randomized controlled trial by Diamond et al. published in the Journal of Sexual Medicine demonstrated statistically significant increases in sexual desire events in premenopausal women with hypoactive sexual desire disorder (HSDD) over a 24-week period. The subcutaneous administration route used in that study (doses of 0.75mg and 1.25mg) is consistent with the reconstitution math described in this guide β€” underscoring why precise dilution is foundational to replicating published protocols.

Commonly Referenced Research Protocols

Published literature and registered clinical trials have examined PT-141 at the following dose ranges β€” presented here for research reference only:

  • 0.5mg–1.25mg subcutaneous: Range studied in Phase II trials for HSDD in women, including the Diamond et al. and Safarinejad studies.
  • 1.25mg–1.75mg: Range explored in male sexual dysfunction studies, including Rosen et al. (2004), which examined response in men with erectile dysfunction who were non-responsive to sildenafil.
  • Timing: Most protocols log outcomes at 2–6 hours post-administration, consistent with PT-141's reported plasma half-life of approximately 2.7 hours.

For research teams working with multiple peptides, the reconstitution calculator supports multi-peptide workflows, letting you calculate volumes for concurrent vials without switching between spreadsheets.

PT-141 Storage: Pre- and Post-Reconstitution

Lyophilized PT-141 powder is stable at room temperature (up to 25Β°C) for short transport periods, but long-term storage should be at –20Β°C to –80Β°C, protected from light and humidity. Once reconstituted:

  • Refrigerated (2–8Β°C): Use within 28 days when reconstituted with bacteriostatic water.
  • Frozen (–20Β°C): Some labs freeze aliquots post-reconstitution for longer-term storage. Minimize freeze-thaw cycles β€” no more than 2–3 per aliquot is the general guideline.
  • Light: Amber vials or foil wrapping recommended. Peptide bonds can degrade under prolonged UV exposure.
  • Inspection: Before each draw, visually inspect for cloudiness, particulates, or color change. Discard if any are present.
PT-141 Storage Timeline Lyophilized Room Temp Short transit only Lyophilized –20Β°C to –80Β°C Months–years unopened Reconstitute + BAC Water Use calculator ↑ here Reconstituted 2–8Β°C fridge Up to 28 days with BAC water

Common Reconstitution Errors to Avoid

Even experienced researchers make these mistakes. A PT-141 peptide reconstitution calculator prevents most of them, but understanding the root cause is valuable:

  • Injecting water directly onto the powder cake: Creates mechanical shear and foaming, denaturing some peptide. Always direct the stream to the vial wall.
  • Using the wrong syringe type: Mixing up U-40 and U-100 insulin syringes is one of the most common volume errors in peptide research. A U-40 syringe at 20 units delivers 0.5mL, not 0.2mL β€” a 150% overdose relative to a U-100 at the same marking.
  • Not accounting for vial dead volume: Standard vials retain 0.05–0.1mL of solution that cannot be drawn. Factor this into total dose calculations for multi-dose protocols.
  • Skipping the label: Unlabeled vials in a shared lab freezer are a source of serious protocol errors. Date, concentration, and peptide identity should be on every vial.
  • Reconstituting too large a volume: Adding excess BAC water lowers concentration and forces larger draw volumes, increasing measurement imprecision on small syringes.

PT-141 in Research Stacks

PT-141 is sometimes studied alongside other peptides in multi-compound research designs. Common pairings in published literature and registered trials include:

  • PT-141 + BPC-157: Investigated for potential synergistic effects on CNS signaling and tissue repair, though direct combination studies remain limited as of 2026.
  • PT-141 + Kisspeptin analogs: Both act upstream in the HPG axis; combination protocols appear in reproductive endocrinology research.

When running multi-peptide protocols, calculate each vial's concentration separately using the peptide calculator to avoid cross-contamination of dosing math.

Research Use Only Disclaimer: PT-141 (bremelanotide) and all peptides referenced in this article are intended for laboratory research purposes only. They are not approved for human consumption, are not dietary supplements, and should not be used for self-administration. All dosing information is presented as a reference to published scientific literature.

Frequently Asked Questions

How much bacteriostatic water should I add to a 10mg PT-141 vial?

The most common research standard is 2.0mL of bacteriostatic water, yielding a 5mg/mL stock concentration. This gives convenient draw volumes: 10 units (0.1mL) for 0.5mg, 20 units (0.2mL) for 1.0mg, and 40 units (0.4mL) for 2.0mg on a U-100 insulin syringe. Use the Capital Peptides calculator if you prefer a different target concentration.

What is the difference between U-100 and U-40 insulin syringes for PT-141 reconstitution?

U-100 syringes measure 1mL across 100 units (0.01mL per unit); U-40 syringes measure 1mL across 40 units (0.025mL per unit). Drawing 20 units on a U-100 gives 0.2mL, while 20 units on a U-40 gives 0.5mL β€” a 150% difference. Always confirm your syringe type before drawing a dose from a reconstituted peptide vial.

How long does reconstituted PT-141 remain stable?

When reconstituted with bacteriostatic water and stored at 2–8Β°C in a refrigerator, PT-141 solution is generally considered stable for up to 28 days. Sterile water preparations should be used immediately or discarded. Lyophilized (unreconstituted) powder stored at –20Β°C can remain viable for much longer periods.

Can I use the PT-141 peptide reconstitution calculator for other peptides?

Yes. The Capital Peptides reconstitution calculator is designed for any lyophilized peptide vial. Enter the vial's peptide mass (mg), your desired solvent volume (mL), and target dose, and it calculates concentration and draw volume regardless of the specific peptide.

What does PT-141 target pharmacologically?

PT-141 (bremelanotide) is a melanocortin receptor agonist with selectivity for MC3R and MC4R subtypes. It acts centrally via hypothalamic dopaminergic pathways, making its mechanism of action distinct from peripherally acting compounds. MC4R activation in the medial preoptic area is the primary pathway studied in sexual arousal and motivation research.

References

  1. Diamond, L.E., Earle, D.C., Rosen, R.C., Willett, M.S., & Molinoff, P.B. (2004). Double-blind, placebo-controlled evaluation of the safety, pharmacokinetic properties and pharmacodynamic effects of intranasal PT-141, a melanocortin receptor agonist, in healthy males and patients with mild-to-moderate erectile dysfunction. International Journal of Impotence Research, 16(1), 51–59. doi.org/10.1038/sj.ijir.3901139
  2. Safarinejad, M.R. (2008). Evaluation of the safety and efficacy of bremelanotide, a melanocortin receptor agonist, in female subjects with arousal disorder: A double-blind placebo-controlled, fixed-dose, randomized study. Journal of Sexual Medicine, 5(4), 887–897. doi.org/10.1111/j.1743-6109.2007.00698.x
  3. Rosen, R.C., Diamond, L.E., Earle, D.C., Shadiack, A.M., & Molinoff, P.B. (2004). Evaluation of the safety, pharmacokinetics and pharmacodynamic effects of subcutaneously administered PT-141, a melanocortin receptor agonist, in healthy male subjects and in patients with an inadequate response to Viagra. International Journal of Impotence Research, 16(2), 135–142. doi.org/10.1038/sj.ijir.3901200
  4. Kingsberg, S., Kellogg, S., & Krychman, M. (2009). Treating dyspareunia caused by vaginal atrophy: A review of treatment options using vaginal estrogen therapy. International Journal of Women's Health, 1, 105–111. Referenced for HSDD prevalence context in melanocortin research. doi.org/10.2147/IJWH.S4872
  5. U.S. National Library of Medicine. (2019). Bremelanotide (Vyleesi) drug approval package. FDA Center for Drug Evaluation and Research. accessdata.fda.gov